Table 1.
Clinical characteristics of patients in the validation datasets.
| SPORE New data | GSE13213 Tomida2009 | GSE11969 Matsuyama2011 | GSE8894 Lee2008 | GSE3141 Bild2006 | GSE4573 Raponi2006 | GSE14814 Zhu2010 | |
|---|---|---|---|---|---|---|---|
|
| |||||||
| Total Patients | n = 176 | n = 117 | n = 149 | n = 138 | n = 111 | n = 129 | n = 90 |
| Gender | |||||||
| Female | 83 (47.2%) | 57 (48.7%) | 48 (32.2%) | 34 (24.6%) | - | 47 (36.4%) | 23 (25.6%) |
| Male | 93 (52.8%) | 60 (51.3%) | 101 (67.8%) | 104 (75.4%) | - | 82 (63.6%) | 67 (74.4%) |
|
| |||||||
| Stage | |||||||
| I | 112 (63.6%) | 79 (67.5%) | 78 (52.3%) | - | 62 (55.9%) | 73 (56.6%) | 45 (50.0%) |
| II | 32 (18.2%) | 13 (11.1%) | 26 (17.4%) | - | - | 33 (25.6%) | 45 (50.0%) |
| III | 30 (17.0%) | 25 (21.4%) | 45 (30.2%) | - | - | 23 (17.8%) | - |
| IV | 1 (0.6%) | - | - | - | - | - | - |
| Unknown | 1 (0.6%) | - | - | 138 (100%) | 49 (44.1%) | - | - |
|
| |||||||
| Histology | |||||||
| ADCs | 133 (75.6%) | 117 (100%) | 90 (60.4%) | 62 (44.9%) | 58 (52.3%) | - | 28 (31.1%) |
| SCCs | 43 (24.4%) | - | 35 (23.5%) | 76 (55.1%) | 53 (47.7%) | 129 (100%) | 52 (57.8%) |
| Others | - | - | 24 (16.1%) | - | - | - | 10 (11.1%) |
|
| |||||||
| Median Follow-up (Months) | 47.4 | 68 | 78 | 41.8 | 31.1 | 34.2 | 64.8 |
|
| |||||||
| Platform | Illumina Human-WG6 V3 | Agilent 44K | Agilent 21.6K custom array | Affy U133 Plus_2 | Affy. U133 Plus_2 | Affy. U133A | Affy. U133A |